To the Editor:
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has led to a major public health challenge. The high virulence and transmissibility of SARS-CoV-2 requires strong health-care policy actions to reduce its spread. Since February 21, the SARS-CoV-2 outbreak smashed Northern and Central Italy and on March 9th the Italian government introduced a lockdown which lasted until May 3rd. Meanwhile non-urgent clinical care activity was deferred, potentially negatively impacting on patients with chronic diseases, including patients with cirrhosis. Whether the lockdown determined clinical consequences in patients with cirrhosis is unknown. Herein we evaluated the characteristics, clinical course, in-hospital and 90-day mortality as well as the 30-day readmission rate in patients hospitalized for an acute decompensation of cirrhosis from March 2020 to April 2020 in 2 centers in Northern/Center Italy. Their characteristics and outcomes were compared with those of patients admitted in March-April 2019.

Patients were retrospectively identified and demographic, clinical and laboratory data were collected reviewing electronic and paper charts. Data on readmissions and mortality at 90 days were collected as well.

During the lockdown non-urgent visits were deferred and telemedicine/phone contacts were implemented. Day hospital activity for planned procedures (e.g. large volume paracentesis) and outpatient visits for patients at high risk of readmissions (readmitted in the prior 30 days, with acute-on-chronic liver failure during hospitalization or Child-Pugh class C) were maintained. Overall, we observed a 65% reduction in outpatient visits.

We identified 100 patients admitted for acute decompensation of cirrhosis, 55 were admitted in 2019 and 45 in 2020. Demographic characteristics and reasons for hospitalization were similar between the 2 groups (Table 1). Bilirubin was significantly higher in patients admitted during the lockdown (116 vs. 65 μmol/L; p = 0.032). There was a trend toward a higher model for end-stage liver disease-sodium (MELD-Na) score in patients admitted during the lockdown (22 vs. 19; p = 0.071). In spite of a similar rate of bacterial infections at admission, the level of C-reactive protein tended to be higher in patients admitted during the lockdown (45 vs. 29 mg/L; p = 0.057). Finally, patients admitted during the lockdown more frequently had acute kidney injury (AKI) at admission (42 vs. 22%; p = 0.028). In-hospital mortality and probability of 90-day survival were not significantly different between the 2 groups (7% vs. 7%; p = 1.00; and 23% vs. 25%; p = 0.951; Fig. 1). The proportion of patients transplanted within 90 days was not significantly different between patients admitted during the lockdown and those admitted in 2019 (7% vs. 13%; p = 0.505). After discharge, 21 out of 40 patients discharged alive during the lockdown were referred to the outpatient clinic for early post discharge management (53% vs. 81% in 2019; p = 0.004). 4 were lost to follow-up while the remaining were followed up by telemedicine/phone contact. The proportion of patients readmitted within 30 days was not significantly different in lockdown and control groups (23 vs. 21%; p = 0.920).

This study showed 2 main findings. The first is that during the lockdown patients admitted to the hospital for an acute decompensation of cirrhosis had a more advanced liver disease, a higher proportion of AKI and higher inflammatory biomarkers. One may hypothesize that during the lockdown patients with cirrhosis delayed their access to medical care because of concerns over contracting COVID-19 in hospital. This is relevant for patients with cirrhosis that are at risk of severe COVID-19 and is in keeping with the delayed access to care observed for patients with stroke and myocardial infarction during the peak of the COVID-19 outbreak in Spain and England. Anyway, this is a speculation that has to be proven in well-designed studies. Despite a more severe disease at admission, we did not find an increase in mortality rate in patients admitted during the lockdown, however the sample size was underpowered to identify such a difference. In preparing to face the new COVID-19 outbreaks worldwide, patients with cirrhosis should be advised to seek care without delay when signs of decompensation/infection occur.

In keeping with data of other Italian Hepatology units, outpatient activity was significantly reduced in our center during the lockdown. One potential drawback of this reduction could be the increase of early readmissions for patients discharged. The second main finding of this study is that the reorganization of outpatient management (prioritizing urgent visits and those for patients at risk of readmissions) could have mitigated the risk of early readmissions. This was obtained with no undermining of patient and staff safety. All physicians and nurses at our institutions wore personal protective equipment during visits and a negative nasopharyngeal swab was required within a week for patients before their planned day admission. None of the medical staff contracted SARS-CoV-2 infection during the study period.

In conclusion, a reorganization of outpatient management, prioritizing visits for high-risk patients and maintaining...
day hospital activity, mitigated the risk of 30-day readmissions and 90-day mortality for patients admitted for decompensated cirrhosis during lockdown. Such a policy was effective for a short-term lockdown period. Whether that policy is safe for longer periods of lockdown is yet to be explored; similarly, unintended long-term consequences for less sick patients should be better explored in the future.

### Financial support
The authors received no financial support to produce this manuscript.

### Conflict of interest
The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

### Authors’ contributions
SP: Study concept and design, collection of data, analysis and interpretation of data, drafting of the manuscript. MM: Study concept and design, collection of data, study supervision, interpretation of data, drafting of the manuscript, critical revision for important intellectual content. PA: Study concept and design, study supervision, interpretation of data, drafting of the manuscript, critical revision for important intellectual content.
Supplementary data
Supplementary data to this article can be found at https://doi.org/10.1016/j.jhepr.2021.100229.

References
Author names in bold designate shared co-first authorship

[1] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–273.

[2] Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol 2020;73:441–445.

[3] Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 2013;59. https://doi.org/10.1016/j.jhep.2013.03.010.

[4] Piano S, Morando F, Carretta G, Tonon M, Vettore E, Rosi S, et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol 2017;112. https://doi.org/10.1038/ajg.2017.253.

[5] Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020. https://doi.org/10.1016/j.jhep.2020.06.001.

[6] Bajaj JS, Garcia-Tsao G, Biggins SW, Kamath PS, Wong F, McGeorge S, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multi-centre matched cohort. Gut 2020. https://doi.org/10.1136/gutjnl-2020-322118.

[7] Montaner J, Barragán-Prieto A, Pérez-Sánchez S, Escudero-Martínez I, Moniche F, Sánchez-Miura JA, et al. Break in the stroke chain of survival due to COVID-19. Stroke 2020;51:2307–2314.

[8] Kwok CS, Gale CP, Kinnaird T, Curzen N, Ludman P, Kontopantelis E, et al. Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart 2020. https://doi.org/10.1136/heartjnl-2020-317650.

[9] Aghemo A, Masarone M, Montagnese S, Petta S, Ponziani FR, Russo FP. Assessing the impact of COVID-19 on the management of patients with liver diseases: a national survey by the Italian association for the study of the Liver. Dig Liver Dis 2020;52:937–941.

Salvatore Piano1,*
Marco Marzioni2
Paolo Angeli1
on behalf of the COVID-CIRRHOSIS study group†

1Department of Medicine – DIMED, University and Hospital of Padova, Padova, Italy;
2Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche – “Ospedali Riuniti” University Hospital, Ancona, Italy

†COVID-CIRRHOSIS study group collaborators are listed at the end of the letter.

COVID-CIRRHOSIS study group
Marta Tonon, Department of Medicine – DIMED, University and Hospital of Padova, Padova, Italy
Marta Mazzetti, Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche – “Ospedali Riuniti” University Hospital, Ancona, Italy
Valeria Calvino, Department of Medicine – DIMED, University and Hospital of Padova, Padova, Italy
Lucia Maroni, Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche – “Ospedali Riuniti” University Hospital, Ancona, Italy
Patrizia Pontisso, Department of Medicine – DIMED, University and Hospital of Padova, Padova, Italy

* Corresponding author. Address: Unit of Internal Medicine and Hepatology, Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35100 Padova, Italy, Telephone: 0039/0498212265, Fax: 0039/0498218676.
E-mail address: salvatorepiano@gmail.com (S. Piano).